Chronic obstructive pulmonary disease (COPD) and lung cancer are the third and sixth most common causes of death worldwide. One major challenge is that there are no effective screening methods capable of early detection of these diseases and when these diseases are finally detected, they are often at advanced stages for which few effective treatment strategies exist. In the case of lung cancer, more than half of people die within the year of diagnosis. Darkfield (scattering-based) x-ray contrast has been recently demonstrated to provide exciting capabilities for early detection of lung pathologies, including cancer and COPD at doses comparable to conventional chest radiography. This contrast mechanism differs significantly from current approaches, which use the absorption of x-rays for contrast rather than the scattering of x-rays. Accessing information provided by this contrast mechanism requires an emerging grating-based x-ray technique called Talbot-Lau interferometry, which uses three sets of gratings (source, phase, and detector) to achieve contrast. However, a critical bottleneck for using this technique at the high x-ray energies (~60 keV) required for imaging through a human chest is a source grating with the aspect ratios required cannot be fabricated. We propose to develop a lung darkfield imaging prototype using a major x-ray source innovation that removes the need for the x-ray source grating to enable Talbot-Lau interferometry at high x-ray energies. The system will critically enable demonstrations of the clinical potential of darkfield radiography for early detection of lung pathologies. The proposed Phase I 6-month project is a proof-of-principle of a grating-less Talbot-Lau breadboard set-up on a phantom. The proposed Phase II 24-month project is to develop a complete prototype system and experimentally verify its performance.

Public Health Relevance

Lung diseases (e.g. lung cancer and chronic obstructive pulmonary disease) are devastating high mortality diseases that currently lack life-saving screening methods. This project proposes to develop a lung screening system that employs recent advances in darkfield x-ray imaging, which provides the sensitivity for critically needed early detection of lung diseases and at doses comparable to conventional chest x-rays. The implementation of a widespread screening method could enable early treatment and significantly impact survival outcomes of COPD and lung cancer, which are the fourth and seventh most common causes of death worldwide.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
1R44HL154950-01
Application #
10082257
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Gan, Weiniu
Project Start
2020-09-01
Project End
2021-03-31
Budget Start
2020-09-01
Budget End
2021-03-31
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Sigray, Inc.
Department
Type
DUNS #
079183051
City
Concord
State
CA
Country
United States
Zip Code
94520